EyePoint Pharmaceuticals, Inc. (EYPT) financial statements (2020 and earlier)

Company profile

Business Address 480 PLEASANT STREET
WATERTOWN, MA 02472
State of Incorp. DE
Fiscal Year End December 31
SIC 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
6/30/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments22391729291810
Cash and cash equivalents2239171519157
Short-term investments   14933
Receivables      1
Inventory, net of allowances, customer advances and progress billings2    
Inventory2      
Other undisclosed current assets17111112
Total current assets:42401830301912
Noncurrent Assets
Operating lease, right-of-use asset3
Property, plant and equipment0000000
Intangible assets, net (including goodwill)283101233
Intangible assets, net (excluding goodwill)283101233
Restricted cash and investments000000 
Other undisclosed noncurrent assets  00000
Total noncurrent assets:313212334
TOTAL ASSETS:73721932322316
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities11755434
Accounts payable4311101
Accrued liabilities7444322
Employee-related liabilities    111
Deferred revenue0
Debt0      
Deferred revenue and credits 00001
Other undisclosed current liabilities 15  (1)(1)(1)
Total current liabilities:122255323
Noncurrent Liabilities
Long-term debt and lease obligation5017     
Long-term debt, excluding current maturities4717     
Operating lease, liability3
Liabilities, other than long-term debt32106665
Deferred revenue and credits 06665
Other liabilities31     
Derivative instruments and hedges, liabilities 20     
Total noncurrent liabilities:533806665
Total liabilities:6560511989
Stockholders' equity
Stockholders' equity attributable to parent812132123158
Common stock0000000
Additional paid in capital473375323312293291270
Accumulated other comprehensive income1111111
Accumulated deficit(465)(364)(311)(292)(271)(277)(264)
Total stockholders' equity:812132123158
TOTAL LIABILITIES AND EQUITY:73721932322316

Income statement (P&L) ($ in millions)

12/31/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
6/30/2013
Revenue, net 822732
Gross profit:203822732
Operating expenses(68)(29)(26)(23)(20)(17)(14)
Operating income (loss):(48)(26)(19)(22)6(13)(12)
Nonoperating income (expense)(9)(26)00000
Investment income, nonoperating (26)  000
Other nonoperating income (expense)10000(0)(0)
Interest and debt expense(4)(1)     
Income (loss) from continuing operations before equity method investments, income taxes:(61)(53)(18)(22)6(13)(12)
Other undisclosed income from continuing operations before income taxes4      
Income (loss) from continuing operations before income taxes:(57)(53)(18)(22)6(13)(12)
Income tax expense (benefit)   0(0)00
Net income (loss) available to common stockholders, diluted:(57)(53)(18)(22)6(13)(12)

Comprehensive Income ($ in millions)

12/31/2019
6/30/2018
6/30/2017
6/30/2016
6/30/2015
6/30/2014
6/30/2013
Net income (loss):(57)(53)(18)(22)6(13)(12)
Other comprehensive income (loss)00(0)(0)(0)0(0)
Comprehensive income (loss), net of tax, attributable to parent:(57)(53)(19)(22)6(13)(12)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: